INmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call Transcript
INmune Bio, Inc. beats earnings expectations. Reported EPS is $-0.47, expectations were $-0.58.
Inmune Bio Inc. (INMB)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Rhenman & Partners Asset Management Henrik Rhenman | 178,284 | $2,007,478 | 0.2% | |
| 2. | Citadel Investment Group Ken Griffin | 33,851 | $381,162 | +138% | 0% |
| 3. | Millennium Management Israel Englander | 24,204 | $272,537 | 0% | |
| 4. | Balyasny Asset Management Dmitry Balyasny | 23,258 | $261,885 | 0% | |
| 5. | 683 Capital Partners Ari Zweiman | 19,253 | $216,789 | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.32 | 18,028 | Large Shareholder, Officer | 1,268,179 | 2024-04-19 | Filing | |
| $8.32 | 18,028 | Large Shareholder, Officer, Director | 1,538,726 | 2024-04-19 | Filing | |
| $8.32 | 14,423 | Large Shareholder, Officer | 1,510,806 | 2024-04-19 | Filing | |
| $8.32 | 29,603 | Director | 66,603 | 2024-04-19 | Filing | |
| $6.95 | 7,000 | Director | 37,000 | 2023-11-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $11.01 | 10,000 | Director | 82,187 | 2023-07-12 | Filing | |
| $20.00 | 701 | Large Shareholder, Officer | 1,472,793 | 2021-11-03 | Filing | |
| $20.00 | 1,025 | Large Shareholder, Officer | 1,219,158 | 2021-11-03 | Filing | |
| $20.00 | 3,626 | Large Shareholder, Officer, Director | 1,490,674 | 2021-11-03 | Filing | |
| $20.00 | 6,517 | Large Shareholder, Officer, Director | 1,494,300 | 2021-10-27 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 541,329 | $6,095,364 | 0% | |
| 2. | 257,929 | $2,904,282 | 0% | |
| 3. | 170,040 | $1,914,965 | 0% | |
| 4. | 109,848 | $1,236,888 | 0% | |
| 5. | 98,012 | $1,103,615 | 0.01% |
News See All
INmune Bio, Inc. (NASDAQ:INMB) Q3 2023 Earnings Call Transcript
Operator: Greetings and welcome to the INmune Bio Third Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.
15 Most Shorted Stocks That Are Loved By Analysts
In this piece, we will take a look at the 15 most shorted stocks that are loved by analysts.
INmune Bio, Inc. (NASDAQ:INMB) Q2 2023 Earnings Call Transcript
Operator: Greetings, and welcome to the INmune Bio Second Quarter 2023 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded.
INmune Bio, Inc. (NASDAQ:INMB) Q1 2023 Earnings Call Transcript
Operator: Good day and welcome to the INmune Bio First Quarter 2023 Earnings Conference Call. All participants will be in a listen-only mode. Please note today's event is being recorded.
INmune Bio, Inc. (NASDAQ:INMB) Q4 2022 Earnings Call Transcript
Operator: Greetings, and welcome to the INmune Bio Fourth Quarter and Full Year 2022 Earnings Call. This conference will be recorded.
10 Best Micro-Cap Stocks to Invest In
As the economy comes back to normal, investors are beginning to pay attention to small companies that are operating in high-growth sectors.
Where Do Hedge Funds Stand On Inmune Bio Inc. (INMB)?
As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade.
Do Hedge Funds Love Inmune Bio Inc. (INMB)?
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities...
Billionaire Hedge Funds
